{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:27:53Z","timestamp":1791563273220,"version":"4.3.4"},"reference-count":53,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["SHSESP17\u2010055"],"award-info":[{"award-number":["SHSESP17\u2010055"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The introduction of protein kinase inhibitors (PKIs) for chronic myeloid leukaemia (CML) has considerably improved prognosis of the disease but has also demonstrated a great potential for drug\u2013drug interactions. Using the French health insurance databases, we aim to investigate the frequency, identify the associated factors and describe the potential consequences of potential drug\u2013drug interactions (pPKI\u2010DIs) between PKIs and concurrent medications in CML. A retrospective cohort study has been performed among patients with CML identified in the French healthcare database from 2011 to 2014. A pPKI\u2010DI is defined as the presence of drugs listed as \u2018interacting\u2019 on the same day as PKI dispensing (co\u2010dispensing) or in its coverage period (co\u2010medication) during the first year of follow\u2010up. The list of interacting drugs is based on the summary of products characteristics (SPCs) and Thesaurus of interactions. We performed specific nested case\u2013control comparisons to investigate the association between PKI\u2010DI and each of the three potential outcomes (death, hospitalisation for adverse drug reactions and switch to another PKI). We included 3480 patients; 1429 (41%) had a co\u2010dispensing pPKI\u2010DI, and 2153 (62%) had a co\u2010medication pPKI\u2010DI; 50% of the pPKI\u2010DIs were \u2018to be taken into account\u2019, and 17% were \u2018not recommended\u2019. The PKI with the most interactions was imatinib, and additional common drug classes included statins, benzodiazepines and proton pump inhibitors. Multivariate analysis demonstrated that the use of a higher number of additional drugs, comorbidities at baseline, high number of prescribers and higher ages were potential risk factors. Nilotinib and dasatinib showed a tendency towards a higher risk of pPKI\u2010DI compared to imatinib. Despite the fact that some PKI\u2010DIs were potentially clinically relevant, we did not find any significant association with death, hospitalisation for adverse drug reactions and switching. These findings should increase awareness to help reduce the prevalence of PKI\u2013drug interactions and thereby ensure better management of CML patients.<\/jats:p>","DOI":"10.1111\/fcp.12899","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T02:54:19Z","timestamp":1681786459000},"page":"994-1005","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Drug\u2013drug interactions of protein kinase inhibitors in chronic myeloid leukaemia patients: A study using the French health insurance database"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8131-8851","authenticated-orcid":false,"given":"Marie","family":"Pajiep","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire de Toulouse  Toulouse France"},{"name":"Universit\u00e9 Toulouse III Paul Sabatier  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-5873","authenticated-orcid":false,"given":"Maryse","family":"Lapeyre\u2010Mestre","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Toulouse  Toulouse France"},{"name":"Universit\u00e9 Toulouse III Paul Sabatier  Toulouse France"},{"name":"INSERM CIC1436 CIC  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Despas","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Toulouse  Toulouse France"},{"name":"Universit\u00e9 Toulouse III Paul Sabatier  Toulouse France"},{"name":"INSERM CIC1436 CIC  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29889"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100776\u20102"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12007"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25792"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.675609"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2005.03.007"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.4103\/picr.PICR_55_18"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(13)70579\u20105"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918818347"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1887"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12496"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1312"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw019"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094\u2010012\u20100767\u20105"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201007\u2010294330"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2335"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010016\u20100503\u20103"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31917"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.080424"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12769"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.182"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1515\/dmdi\u20102014\u20100026"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010016\u20102108\u2010z"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ped.12382"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010016\u20102115\u20100"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000366132"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005076"},{"issue":"4","key":"e_1_2_12_30_1","first-page":"1719","article-title":"Drug\u2010drug interactions in patients using tyrosine kinase inhibitors: a multicenter retrospective study","volume":"24","author":"Ergun Y","year":"2019","journal-title":"J BUON off J Balk Union Oncol"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216682311"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010018\u20103413\u20107"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2014.11.009"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12214"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4233"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2018.09.076"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12592"},{"key":"e_1_2_12_38_1","unstructured":"WHOCC. \u2010Definition and general considerations. Accessed February 14 2022.https:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12544"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010022\u201006968\u2010w"},{"key":"e_1_2_12_41_1","volume-title":"Summary of product characteristics","author":"EMA"},{"key":"e_1_2_12_42_1","unstructured":"glivec\u2010epar\u2010product\u2010information_en.pdf. Accessed October 3 2022.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/glivec-epar-product-information_en.pdf"},{"key":"e_1_2_12_43_1","unstructured":"iclusig\u2010epar\u2010product\u2010information_en.pdf. Accessed October 3 2022.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/iclusig-epar-product-information_en.pdf"},{"key":"e_1_2_12_44_1","unstructured":"sprycel\u2010epar\u2010product\u2010information_en.pdf. Accessed October 3 2022.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sprycel-epar-product-information_en.pdf"},{"key":"e_1_2_12_45_1","unstructured":"tasigna\u2010epar\u2010product\u2010information_en.pdf. Accessed October 3 2022.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tasigna-epar-product-information_en.pdf"},{"key":"e_1_2_12_46_1","unstructured":"bosulif\u2010epar\u2010product\u2010information_en.pdf. Accessed October 3 2022.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bosulif-epar-product-information_en.pdf"},{"key":"e_1_2_12_47_1","unstructured":"Thesaurus des interactions medicamenteuses. Published online2020:257."},{"key":"e_1_2_12_48_1","volume-title":"ATC classification and DDD assignment. 16th edition. WHO Collaborating Centre for Drug Statistics Methodology","author":"WHO Collaborating Centre for Drug Statistics Methodology"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000471"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5368"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp400403s"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02472\u20102018"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001329"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006189"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T12:36:13Z","timestamp":1694176573000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/fcp.12899"],"URL":"https:\/\/doi.org\/10.1111\/fcp.12899","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"2022-07-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}